Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q3 2024

Cerevel Therapeutics reports successful 2022, eyes transformative neuroscience advancements

Cerevel Therapeutics had a productive year, focusing on transformative neuroscience.
Strong financial position with cash resources to fund operations into 2025.
Facing challenges with trial delays but addressing them with mitigation plans.
Opportunities lie in upcoming data readouts and exploring new indications.

Cerevel Therapeutics reports strong financials, navigates trial challenges for growth

Cerevel Therapeutics is well-positioned financially with a focus on operational efficiency and trial success, supported by strong cash reserves.
The company faces challenges in pipeline management and trial enrollment dynamics, necessitating strategic adjustments and careful oversight.
Opportunities lie in external growth initiatives, potential product approvals, and expanding therapeutic reach through strategic trial designs.

Cerevel Therapeutics advances key programs amidst challenges, eyes growth opportunities

Cerevel Therapeutics is making progress in key programs, leveraging its strong balance sheet and commitment to patients. Challenges in trial delays and patient selection criteria persist, but the company's focus on quality data and financial strength bode well for future growth.

Cerevel Therapeutics excels in Q3 with robust pipeline and financials

Cerevel Therapeutics demonstrated robust performance in Q3 2023, driven by a strong pipeline and solid financial foundation.
While facing challenges like high rollover rates and data disclosure timelines, the company is well-positioned to capitalize on transformative opportunities.
Strategic focus on quality, innovation, and market expansion underscores Cerevel's commitment to advancing novel therapies for neurological disorders.
With key data readouts expected in 2024 and a clear roadmap for regulatory filings, Cerevel is poised for significant growth and impact in the neurology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration

Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Anthony Coles - Chairperson and Chief Executive Officer Raymond Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Mark Bodenrader - Interim Chief Financial Officer Abraham Ceesay - President Conference Call Participants Umer Raffat - Evercore Michael Yee - Jefferies Paul Matteis - Stifel Tazeen Ahmad - Bank of America Max Skor - Morgan Stanley Mohit Bansal - Wells Fargo Rob Palermo - Goldman Sachs Charles Duncan - Cantor Fitzgerad Douglas Tsao - H.C. Wainwright Operator Good morning, and welcome to the Cerevel Therapeutics Third Quarter 2022 Financial Results Conference Call.

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2022 Earnings Call Transcript

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline

Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Cerevel Therapeutics (CERE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Cerevel Therapeutics (CERE) Might Surprise This Earnings Season

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open.

Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022. Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at 9:20AM ET.

Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading lower by 7.1% to $32.00 during Tuesday's trading session after the company priced its underwritten common stock offering of 7.25 million shares at $35 per share. What Else?

Cerevel Therapeutics Stock Is Falling: Here's Why

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 1,087,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on August 16, 2022, subject to customary closing conditions.

Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes

CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced private offering of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, Cerevel granted the initial purchasers of the notes a 13-day option to purchase up to an additional $45.0 million aggregate principal amount of the notes. The offering is expected to close on August 16, 2022, subject to customary closing conditions.

Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, Cerevel expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of the notes. The offering of the notes is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q2 2022 Earnings Conference Call August 1, 2022 8:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Mark Bodenrader - Interim Chief Financial Officer A. Ceesay - President Conference Call Participants Michael Yee - Jefferies Matthew Harrison - Morgan Stanley Paul Matteis - Stifel Tiffany Sun - JPMorgan Douglas Tsao - H.C.

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q2 2022 Results - Earnings Call Transcript

Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024

Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open.

Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of directors. Mr. Varma succeeds Morris Birnbaum, M.D., Ph.D., who announced that he is retiring from his role as Senior Vice President and Chief Scientific Officer of Internal Medicine at Pfizer Inc., and will therefore be stepping down from his position as a director at Cerevel. Dr. Birnbaum has served on the Cerevel board since the company's inception in 2018.

Cerevel Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8 at 10:30 am ET.

Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Matt Calistri - Vice President of Corporate Strategy and Investor Relations Tony Coles - Chairperson and Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Mark Bodenrader - Interim Chief Financial Officer A. Ceesay - President Conference Call Participants Cory Kasimov - JPMorgan Michael Yee - Jefferies Paul Matteis - Stifel Douglas Tsao - H.C.

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q1 2022 Results - Earnings Call Transcript

On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the U.S. financial markets open.

Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy

Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 4th Annual CNS Day on Tuesday, March 29, 2022 at 9:00 a.m. EDT.

Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q4 2021 Results - Earnings Call Transcript

Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open.

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eight days of dosing compared with placebo

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Korn/Ferry Int.

Rexford Industrial Realty

Shareholders of Cerevel Therapeutics Holdings Inc ( CERE , Financial), Rexford Industrial Realty Inc. ( REXR , Financial), and Korn Ferry ( KFY , Financial) saw the value of their shares increase significantly over the past year, outperforming the S&P 500 Index. The benchmark index for the U.S. market stands at 4,477.44 as of Feb. 3, having gained 15% over the past year.

News for Cerevel Therapeutics Holdings Inc Stock (CERE)